内容紹介
Summary
Purpose: There are many reports that describe the effectiveness of aromatase inhibitors as endocrine therapy after breast cancer surgery. However, there are few detailed evaluations of patient adherence to anastrozole(ANA)therapy. Here, we evaluated the adherence to ANA therapy in postoperative patients with primary breast cancer. Methods: We investigated 102 postoperative patients with primary breast cancer without distant metastasis, who received ANA at JCHO Kyusyu Hospital. We calculated the medication continuation rate and disease-free survival at 5 years from the initiation of medication. The reasons for medication discontinuation and alternative drug therapy after ANA therapy discontinuation were also investigated. Results: The 5-year continuation rate of ANA treatment alone was 79%(81/102). The rate of all patients who continued ANA treatment, including 9 who changed to other drugs, was 88%(90/102). The most frequent ANA discontinuation reasons were progressive disease(8 cases), arthritis(5 cases), and nausea(3 cases). The disease-free survival rate was 92%(94/102), and the overall survival rate was 97%(99/102). Conclusion: ANA showed a high continuation rate. Adherence of ANA in postoperative patients with breast cancer was well maintained, even when the treatment was changed to other drugs due to adverse events.
要旨
目的: 乳癌術後内分泌療法におけるアロマターゼ阻害剤の有効性は多数報告されているが,服薬アドヒアランスについて詳細に評価したものは少ない。今回,当院におけるアナストロゾール(ANA)を初回治療とした閉経後原発乳癌術後患者の服薬継続率と服薬中止理由について調査した。方法: 当院で,ANAを投与された遠隔転移のない原発乳癌症例102例を対象に,服薬開始から5年経過時の服薬継続率,無病生存率を算出した。服薬中止理由,中止後に実施された薬物療法についても調査した。結果: 5年経過時の服薬継続率は79%(81/102)であり,他剤に変更したものを含めた継続率は88%(90/102)であった。ANAの服薬中止理由はprogressive diseaseが最多で8例,arthritisが5例,nauseaが3例であった。無病生存率は92%(94/102)で,全生存率は97%(99/102)であった。結論: ANAは高い服薬継続率を示した。有害事象などで他の薬剤に変更になった場合においても閉経後乳癌術後内分泌療法の服薬アドヒアランスは良好に維持されていた。
目次
Purpose: There are many reports that describe the effectiveness of aromatase inhibitors as endocrine therapy after breast cancer surgery. However, there are few detailed evaluations of patient adherence to anastrozole(ANA)therapy. Here, we evaluated the adherence to ANA therapy in postoperative patients with primary breast cancer. Methods: We investigated 102 postoperative patients with primary breast cancer without distant metastasis, who received ANA at JCHO Kyusyu Hospital. We calculated the medication continuation rate and disease-free survival at 5 years from the initiation of medication. The reasons for medication discontinuation and alternative drug therapy after ANA therapy discontinuation were also investigated. Results: The 5-year continuation rate of ANA treatment alone was 79%(81/102). The rate of all patients who continued ANA treatment, including 9 who changed to other drugs, was 88%(90/102). The most frequent ANA discontinuation reasons were progressive disease(8 cases), arthritis(5 cases), and nausea(3 cases). The disease-free survival rate was 92%(94/102), and the overall survival rate was 97%(99/102). Conclusion: ANA showed a high continuation rate. Adherence of ANA in postoperative patients with breast cancer was well maintained, even when the treatment was changed to other drugs due to adverse events.
要旨
目的: 乳癌術後内分泌療法におけるアロマターゼ阻害剤の有効性は多数報告されているが,服薬アドヒアランスについて詳細に評価したものは少ない。今回,当院におけるアナストロゾール(ANA)を初回治療とした閉経後原発乳癌術後患者の服薬継続率と服薬中止理由について調査した。方法: 当院で,ANAを投与された遠隔転移のない原発乳癌症例102例を対象に,服薬開始から5年経過時の服薬継続率,無病生存率を算出した。服薬中止理由,中止後に実施された薬物療法についても調査した。結果: 5年経過時の服薬継続率は79%(81/102)であり,他剤に変更したものを含めた継続率は88%(90/102)であった。ANAの服薬中止理由はprogressive diseaseが最多で8例,arthritisが5例,nauseaが3例であった。無病生存率は92%(94/102)で,全生存率は97%(99/102)であった。結論: ANAは高い服薬継続率を示した。有害事象などで他の薬剤に変更になった場合においても閉経後乳癌術後内分泌療法の服薬アドヒアランスは良好に維持されていた。